Helius Medical Technologies, Inc. announced that it will present results from its new study on the Portable Neuromodulation Stimulator (PoNS®) at the upcoming Consortium of Multiple Sclerosis Centers ...

NEWTOWN, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (HSDT) today announced it will exhibit at the American Academy of Neurology (AAN) Annual Meeting for the first time since ...

-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement ...

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim for payment for the PoNS Device from Aetna Healthcare. The PoNS Device is ...

Helius Medical (HSDT) Technologies announced its first reimbursement payment from a major healthcare provider, Anthem Blue Cross Blue Shield, for its Portable Neuromodulation Stimulator, PoNS, Device.

-- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by patients who have suffered the effects of stroke -- NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Helius ...

NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from ...

NEWTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from ...